SOURCE: World Street Fundamentals

June 27, 2011 09:13 ET

Equity Research on Allergan, Inc. and ISTA Pharmaceuticals, Inc.- Prescribing the Advantage in Bio Pharmaceuticals

HONG KONG--(Marketwire - Jun 27, 2011) - Today, released its industry report highlighting Allergan, Inc. (NYSE: AGN) and ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA). Full fundamental and technical analysis is available at

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

World Street Fundamentals has highlighted Allergan, Inc. as a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company discovers, develops and commercializes specialty pharmaceutical, biologics, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. The entire report on Allergan, Inc. (NYSE: AGN) is available here:

World Street has emphasized ISTA Pharmaceuticals, Inc. as a commercial-stage, multi-specialty pharmaceutical company. It is engaged in developing, marketing and selling its own products in the United States and Puerto Rico. ISTA is a prescription eye care business in the United States and has an allergy drug franchise. ISTA manufactures its finished good products through third-party contracts. As of February 28, 2011, ISTA sold XIBROM (bromfenac ophthalmic solution) 0.09%, which was prescribed for the treatment of inflammation and pain following cataract surgery. The entire report on ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

Contact Information